Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 May-Jun;64(3):290-4.
doi: 10.1016/S0019-4832(12)60089-3.

Levels of cathepsins in acute myocardial infarction

Kavita K Shalia  1 , Manoj R Mashru, Vinod K Shah, Surendra L Soneji, Satchidanand Payannavar
Affiliations

Levels of cathepsins in acute myocardial infarction

Kavita K Shalia et al. Indian Heart J. 2012 May-Jun.

Abstract

Aims/objective: Over expression of matrix degrading enzymes have been implicated in plaque destabilisation and rupture. Cathepsins associated with extracellular matrix breakdown make them intriguing suspects. The aim of the study was to analyse peripheral levels of cathepsin B and cathepsin K and their inhibitor cystatin C during acute myocardial infarction (AMI).

Materials and methods: Study population included AMI patients at acute event (AMI group, n=48), stable angina patients (stable angina group n = 17), and healthy individuals (Control group, n=31). Cathepsin B, cathepsin K, cystatin C, and matrix metalloproteinases (MMP)-9 were analysed by enzyme-linked immunosorbent assay (ELISA) method.

Results: Cathepsin B (45.9%) and cathepsin K (92.31%) at acute event of myocardial infarction (AMI group) increased (P=0.001) while cystatin C decreased marginally (12.5%) as compared to controls. Stable angina group, demonstrated only marginal reduction in all the parameters studied as compared to controls.

Conclusion: Cathepsin B and cathepsin K can be further evaluated as biomarkers in identifying high-risk individuals for AMI.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Circulating levels of cathepsins, cystatin C, and MMP-9 in AMI group. AMI: acute myocardial infarction, MMP: matrix metalloproteinases.
Figure 2
Figure 2
Circulating levels of cathepsins, cystatin C, and MMP-9 in stable angina group. MMP: matrix metalloproteinases.
See this image and copyright information in PMC

References

    1. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation. 1995;92:657–671. - PubMed
    1. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res. 2002;90:251–262. - PubMed
    1. Shi GP, Sukhova GK, Grubb A. Cystatin C deficiency in human atherosclerosis and aortic aneurysms. J Clin Invest. 1999;104:1191–1197. - PMC - PubMed
    1. Liu J, Sukhova GK, Sun JS, Xu WH, Libby P, Shi GP. Lysosomal cysteine proteases in atherosclerosis. Arterioscler Thromb Vasc Biol. 2004;24:1359–1366. - PubMed
    1. Sukhova GK, Shi GP, Simon DI, Chapman HA, Libby P. Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells. J Clin Invest. 1998;102:576–583. - PMC - PubMed